天禾律师 五洲医疗年度股东会法律意见书 安徽天禾律师事务所 关于安徽宏宇五洲医疗器械股份有限公司 2024 年年度股东会法律意见书 天律意 2025 第 01147 号 致：安徽宏宇五洲医疗器械股份有限公司 根据《中华人民共和国公司法》(下称《公司法》)、《中华人民共和国证券 法》（下称《证券法》）、中国证券监督管理委员会《上市公司股东大会规则》 （下称《股东大会规则》）《安徽宏宇五洲医疗器械股份有限公司公司章程》（下 称《公司章程》）等相关规定，以及贵公司（下称公司）与安徽天禾律师事务所 （下称本所）签订的《法律顾问合同》，本所律师出席公司 2024 年年度股东会， 并对本次股东会相关事项进行了见证，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用的原则，对本次股东会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具本法律意见书所需的相关文件 和资料。为出具本法律意见，本所律师审查了公司提供的以下文件： 1 1、《公司章程》； 2、公司 2025 年 ...

安徽宏宇五洲医疗器械股份有限公司 2024 年年度股东会决议公告 一、会议召开情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 1、会议通知情况 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）2024 年年度股 东会通知于 2025 年 4 月 19 日在巨潮资讯网（http://www.cninfo.com.cn）以公告 形式发出。 2、会议召开方式：采用现场投票与网络投票相结合的方式 证券代码：301234 证券简称：五洲医疗 公告编号：2025-020 3、召开时间： （1）现场会议召开时间：2025 年 5 月 15 日（星期四）下午 14：00 （2）网络投票时间：2025 年 5 月 15 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为2025年5月15日（星期四）上午9:15-9:25，9:30- 11:30，下午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 15 日（星期四） ...

Summary of Key Points Core Viewpoint - The report outlines the continuous supervision and compliance measures taken by Everbright Securities for Anhui Hongyu Wuzhou Medical Devices Co., Ltd, highlighting the challenges faced by the company in terms of declining revenue and profit due to global trade policies and market competition [1][4]. Group 1: Company Performance - The company's net profit attributable to shareholders decreased by 33.68%, amounting to 39.97 million yuan, compared to 60.27 million yuan in the same period of 2023 [1]. - Revenue also saw a decline of 10.54%, with a reduction of 5.63 million yuan, totaling 533.68 million yuan [1]. - The company is urged to adopt proactive measures to address international market changes, enhance customer acquisition, control costs, and improve product competitiveness [1]. Group 2: Regulatory Compliance - Everbright Securities has conducted timely reviews of the company's information disclosure documents, with no instances of late reviews [1]. - The company has established and effectively executed regulations to prevent related party transactions and manage fundraising [1]. - A training session was held on December 27, 2024, focusing on compliance with regulations regarding information disclosure and fundraising management [2]. Group 3: Supervision and Governance - The report indicates that there were no significant issues found during the supervision process, and all commitments made by the company and its shareholders were fulfilled [2]. - Everbright Securities has faced regulatory scrutiny, receiving warnings from the China Securities Regulatory Commission and Shenzhen Stock Exchange, prompting a commitment to enhance compliance and internal controls [3][4]. - The company has actively rectified issues raised in regulatory communications and is committed to ensuring accurate and complete information disclosure [4].

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有限公司 2024年年度持续督导跟踪报告 | 保荐机构名称：光大证券股份有限公司 | 被保荐公司简称：五洲医疗 | | --- | --- | | 保荐代表人姓名：黄腾飞 | 联系电话：021-22169999 | | 保荐代表人姓名：林剑云 | 联系电话：021-22169999 | 一、保荐工作概述 | 项目 | | | 工作内容 | | | | --- | --- | --- | --- | --- | --- | | 1.公司信息披露审阅情况 | | | | | | | （1）是否及时审阅公司信息披露文件 | 是 | | | | | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | | | | | 2．督导公司建立健全并有效执行规章制度的 | | | | | | | 情况 | | | | | | | （1）是否督导公司建立健全规章制度（包括 | | | | | | | 但不限于防止关联方占用公司资源的制度、 | 是 | | | | | | 募集资金管理制度、内控制度、内部审计制 | | | | | | | 度、关联交易制度） | | | | ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Wuzhou Medical, which closed at 28.82 yuan, marking a 2.38% increase, with a rolling PE ratio of 54.87, the lowest in 95 days, and a total market capitalization of 1.96 billion yuan [1] - Wuzhou Medical ranks 89th in the medical device industry based on PE ratio, with the industry average at 49.84 and the median at 36.59 [1][2] - As of the first quarter of 2025, three institutions hold shares in Wuzhou Medical, with a total of 293,800 shares valued at 0.08 million yuan [1] Group 2 - Wuzhou Medical specializes in the research, manufacturing, and sales of disposable sterile infusion medical devices, along with other diagnostic and nursing supplies [1] - The company's main products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles [1] - In the latest financial report for the first quarter of 2025, Wuzhou Medical reported revenue of 1.04 million yuan, a year-on-year increase of 15.59%, while net profit was 563,450 yuan, reflecting a year-on-year decrease of 43.00%, with a gross profit margin of 14.62% [1]

光大证券股份有限公司关于安徽宏宇五洲医疗器械股份有 限公司2024年持续督导工作现场检查报告 | 保荐机构名称：光大证券股份有限公司 被保荐公司简称： 五洲医疗 | | | | | | --- | --- | --- | --- | --- | | 保荐代表人姓名：黄腾飞 联系电话：021-52523268 | | | | | | 保荐代表人姓名：林剑云 联系电话：021-52523268 | | | | | | 现场检查人员姓名：黄腾飞 | | | | | | 年 年 月 现场检查对应期间：2023 11 月-2025 | | | 4 | | | 现场检查时间： 年 2025 4 17 | 月 | 日 | | | | 一、现场检查事项 现场检查意见 | | | | | | （一）公司治理 是 否 | | | | 不适用 | | 现场检查手段：查阅公司章程和公司治理制度；查阅公司历次董事会、监事会、 | | | | | | 股东大会会议材料；与公司部分董事、高级管理人及实际控制人进行访谈。 | | | | | | 1.公司章程和公司治理制度是否完备、合规  | | | | | | 2.公司章程和股东会、董事 ...

Group 1: Business Impact and Performance - The impact of recent tariff adjustments on the company's business is limited, with revenue from exports to the U.S. not reaching a significant level [1] - The company has been focusing on enhancing its core business and R&D investments to improve product competitiveness and expand business channels [2] - The company's stock performance is influenced by external factors, including market conditions and investor preferences, despite efforts to optimize governance and enhance shareholder communication [2] Group 2: Financial Performance and Dividends - For the fiscal year 2024, the company plans to distribute a cash dividend of 3 RMB per 10 shares, totaling 20.4 million RMB, with cumulative cash dividends over the past three years amounting to 81.6 million RMB [2] - The company's operating profit increased year-on-year in the first quarter, but net profit declined due to global trade policy changes and increased operational costs [4] Group 3: Future Growth Drivers - The company aims to drive future profitability through innovation, optimizing existing products, and enhancing production efficiency [3] - There are currently 28 ongoing R&D projects, focusing on expanding the product line and entering new markets, including active medical devices [5]

Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in the quarterly report, with no false records, misleading statements, or significant omissions [1][2][8] - The board of directors and supervisory board confirm the quarterly report's compliance with legal and regulatory requirements, reflecting the company's financial status, operating results, and cash flow accurately [10][18] - The first quarter report has not been audited [7][11] Group 2 - The third board of directors' eighth meeting was held on April 25, 2025, with all seven directors present, complying with legal and regulatory requirements [9] - The meeting approved the proposal regarding the first quarter report, confirming its adherence to relevant regulations and accurate reflection of the company's financial situation [10][18] - The voting results for the board meeting were unanimous, with all votes in favor [12] Group 3 - The company will hold the 2024 annual shareholders' meeting on May 15, 2025, using a combination of on-site and online voting [22][24] - The meeting's legal compliance has been confirmed by the board of directors, and all shareholders registered by May 9, 2025, are eligible to attend [23][26] - The meeting will address various proposals, including the independent directors' performance reports [30][32]

证券代码：301234 证券简称：五洲医疗 公告编号：2025-019 安徽宏宇五洲医疗器械股份有限公司 关于召开 2024 年年度股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届董事会第 七次会议决定于 2025 年 5 月 15 日在公司召开 2024 年年度股东会，本次股东会 将采用现场投票和网络投票相结合的方式，根据相关规定，现将股东会的相关事 项提示如下： 一、召开会议的基本情况 1、股东会届次：2024 年年度股东会 2、股东会召集人：公司董事会 3、会议召开的合法、合规性： 4、会议召开时间： （1）现场会议召开时间：2025 年 5 月 15 日（星期四）下午 14:00 （2）网络投票时间：公司同时提供深圳证券交易所交易系统和互联网投票 系统供股东进行网络投票。通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 15 日（星期四）上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网系统投票的具体 ...

安徽宏宇五洲医疗器械股份有限公司 第三届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 证券代码：301234 证券简称：五洲医疗 公告编号：2025-017 安徽宏宇五洲医疗器械股份有限公司（以下简称"公司"）第三届监事会第 七次会议于 2025 年 4 月 25 日以现场结合通讯方式在公司会议室召开，会议于 2025 年 4 月 21 日以邮件和通讯方式通知全体监事。本次会议应出席监事 3 名， 实际出席监事 3 名。 本次会议由公司监事会主席吴国英先生主持，公司董事及高级管理人员列席 了会议。会议的召开符合《公司法》等法律法规、规范性文件和《公司章程》的 规定。 二、监事会会议审议情况 1、审议通过《关于＜2025 年第一季度报告＞的议案》 经审议，监事会认为：公司编制的《2025 年第一季度报告》格式与内容符合 法律、行政法规和中国证监会的规定及深圳证券交易所要求。报告的编制和审议 程序符合法律、行政法规、部门规章、规范性文件和公司章程等规定，报告内容 真实、准确、完整地反映了公司的财务状况、经营成果 ...